Antimicrobial Resistance of Non-Typhoid *Salmonella* in Meat and Meat Products

Sandra M. Rincón-Gamboa 1,2, Raúl A. Poutou-Piñales 2,* and Ana K. Carrascal-Camacho 1

Abstract: *Salmonella enterica* serovars are associated with numerous annual deaths worldwide and are responsible for a large number of foodborne diseases. Within this frame of reference, knowledge of antimicrobial susceptibility represents the fundamental approach of most *Salmonella* treatments. Therefore, scientific publications of antimicrobial susceptibilities and resistance must be precise, with interpretations adjusted to a particular standard. Hence, the three objectives in this study were: (i) to describe the frequency of antimicrobial-resistant isolates of Non-Typhoidal *Salmonella* (NTS) isolated from beef, pork, chicken meat, and other meat products; (ii) to describe the distribution of serovars and their multi-resistance to antibiotics for clinical use (veterinary and human) between 1996 and 2019; and (iii) to propose additional considerations that could improve the use and usefulness of the published results. Our results determined that the predominant isolates came from poultry. Enteritidis and Typhimurium were the most reported serovars by MIC (with both having the highest resistance to TET) while the lowest resistance was to CIP and CRO for Enteritidis and Typhimurium, respectively. The multi-resistance pattern AMP AMC CEP GEN KAN STR TET was the most frequently observed pattern by MIC in Montevideo and Seftenberg, while, for disc diffusion, the pattern AMP STR TET was the most frequent in the Bredeney serotype. In conclusion, researchers should carry out homogeneous sampling procedures, identify the types of the samples, use standard identification methods, and employ appropriate standards for antimicrobial susceptibility interpretation. Additionally, there is also a need for all WHO members to comply with the WHA 73.5 resolution. Our final recommendation is for all producers to reduce antibiotic prophylactic use.

Keywords: multidrug resistance; meat products; standard; non-typhoidal *Salmonella*

1. Introduction

According to the World Health Organization (WHO), foodborne diseases (FBD) are diseases transmitted through contaminated food consumption. Foodborne illnesses include those caused by a microbial pathogen, parasite, chemical contaminant, or biotoxin [1]. The severity of these diseases varies from asymptomatic and mild to life-threatening, in which case life-long treatments are required. In industrialized countries, it is estimated that more than 10% of the population could suffer from a disease associated with contaminated food consumption [2]. One of the agents triggering FBD is *Salmonella* spp., which causes salmonellosis disease with a high morbidity and mortality rate in industrialized and developing countries [3].

*Salmonella* spp., is a Gram-negative bacillus with peritrichously flagella [3]. Moreover, *Salmonella* is a chemoorganotrophic organism and a facultative anaerobe, capable of using both fermentative and respiratory metabolic pathways. *Salmonella* spp. also lacks
cytochrome oxidase, grows on citrate as its unique carbon source, produces sulphuric acid and decarboxylates both lysine and ornithine.

Even though it grows slowly, under favourable conditions it can survive for weeks and months in water and soils. Its optimal growth temperature is 37 °C, yet it can survive between 7 and 48 °C. Nevertheless, growth in food preserved at temperatures between 2 and 4 °C has been described. *Salmonella* spp., is viable at a pH between 4.05 and 9.5, with optimal growth at pH 6.5 and 7.5 ± 0.2 and a water activity (aw) of >0.93. These capabilities cause contamination in food-production chains, since *Salmonella* spp. can survive for a long period of time under food-stored conditions [4,5].

The *Salmonella* genus includes two species, *S. bongori* and *S. enterica* [2,3,6]. *S. enterica* includes six subspecies: *I*, *enterica*; *II*, *salamae*; *IIIa*, *arizonae*; *IIIb*, *diarizonae*; *IV*, *houtenae*; and *V*, *indica* [2].

The subspecies II, IIIa, IIIb, IV and V, can be found in cold-blooded animals and the environment [4] with 1051 serovars, most designated by their antigenic formula [7].

*S. enterica* (subspecies I) strains are most commonly isolated from warm-blooded animals, including fowl and mammals, and it is the most diverse with 1586 serotypes including typhoidal and non-typhoidal species [4]. The serovar names are associated with either the disease they cause or the geographical location where they were isolated from [7], and most of them are non-pathogenic in their reservoirs [6].

Another manner of classifying *Salmonella* spp. is based on the disease it causes. Thus, it can be categorized into typhoidal and non-typhoidal varieties. The non-typhoidal *Salmonella* (NTS) are responsible for gastroenteritis [8] in various hosts. Epidemiologically, they vary in their ability to cause bacteremia and severe human diseases [9]. It has also been estimated that within the overall burden of disease, infections caused by NTS are the second leading cause of diarrheal diseases. Between 1990 and 2010, the burden calculated respectively in disability-adjusted life years (DALYs) was 180–70 per 100,000 [10].

The incubation time after ingestion of non-typhoidal *Salmonella* contaminated food is short (8–72 h). Clinical symptoms of non-typhoidal salmonellosis are associated with acute enterocolitis with abdominal pain, bloody or non-bloody diarrhea [4], nausea, and vomit. The infective dose in contaminated food or water is >10^4 CFU. However, lower doses have been reported in high-fat foods such as meat and poultry. The disease is self-limited (from 5 to 7 days) [4,11,12]. Therefore, the worldwide non-typhoidal disease impact is high, and during the period from 1966 to 2007 there were 93.8 million cases, of which 80.3 million were associated with the consumption of contaminated food, ultimately resulting in 155,000 deaths annually [13].

Transmission of NTS to humans can occur zoonotically due to contact with feces from carrier animals or by consumption of contaminated food [3,4,11,12]. In developing countries, vegetable and water or human to human contact are the main routes of contamination. Whereas, in industrialized countries the chief source of contamination involves consumption of contaminated animal food, particularly fresh meat and eggs [4].

On the other hand, for humans, meat is a concentrated source of nutrients [13]. Therefore, new tendencies have led to the collective need for a constant supply of meat, particularly of beef and pork meat. While beef is more expensive among protein products of animal origin, in developing countries the price of pork meat is more accessible. In contrast, in developed countries, meat is a highly consumed and valued food [14]. Additionally, in the coming years, the world population could surpass 7.5 billion people, stimulating a great meat and meat product demand [15].

The contamination of meat and meat products occurs at different stages in the meat chain (processing, distribution, wholesale, manipulation, and preparation) [16]. Pathogen dissemination occurs in the abattoir, either during the evisceration process or intestinal content removal due to cross-contamination (equipment, utensils and personnel) [4,16–19].

Furthermore, the resistance of *Salmonella* spp. to one or various antimicrobial agents has drastically increased [20–24] as a consequence of uncontrolled use in production systems (i.e., the prevention, control, and treatment of infectious diseases) [24,25]. Moreover,
its prophylactic use as growth promoters in chicken and pigs [19,20,24,26,27] has generated an even greater public health problem, resulting in therapeutic failures in disease treatment for both humans and animals [20,24].

In the European Union in 2016, resistance profiles were found in isolates for 20.4% (95, 434) of human salmonellosis. Sulfonamide/sulfamethoxazole, tetracycline, and ampicillin, and others were among the antibiotics assayed [28]. Antimicrobial resistance in NTS makes infection control and prevention more difficult. Since 1990, S. Typhimurium DT104 strain has increased its global dissemination. According to the National Antimicrobial Resistance Monitoring System (NARMS), in the United States of America, between 2005 and 2006, 4.1% of the isolates decreased their susceptibility to cephalosporins and 84% had resistance phenotypes to multiple antibiotics [3].

There are several methods used to test antimicrobial susceptibility such as the dilution method or minimal inhibitory concentration (MIC) and the Kirby–Bauer disc diffusion method. A combination of the former two methods is referred to as the epsilometric method (E-test) [29]. Additionally, other in vitro assays, such as agar dilution and both macro and microdilutions, have been used. The MIC and disc diffusion methods have been approved by the Clinical and Laboratory Standard Institute (CLSI) and the European Committee on Antimicrobial Susceptibility Testing (EUCAST). The standard released by both entities are frequently updated, hence the importance of following the latest editions [11].

Hence, the objectives of this work were: to describe the frequency of antimicrobial-resistant isolates of Non-Typhoidal Salmonella (NTS) isolated from beef, pork, chicken meat, and meat products; to describe the distribution of serovars and their multi-resistance to antibiotics for clinical use (veterinary and human) between 1996 and 2019; and to propose additional considerations that could improve the use and usefulness of published results.

2. Materials and Methods

2.1. Search Strategy

Web of Science (WoS), SCOPUS, Science Direct, and JSTOR were the websites used to provide comprehensive citation data. The interaction of three groups allowed performing search equations. The first equation included Salmonella/zoonotic salmonella/foodborne pathogen/Nontyphoid Salmonella; the second equation involved antimicrobial resistance, antibiotic resistance/multidrug resistance; and the third involved related meat products/meat poultry/pork/beef by employing “AND” as the Boolean operator [30].

Regional documents were searched at Biblioteca Virtual de Salud (BVS) and PubMed. In BVS and PubMed, DECS (Descriptors in Health Sciences) and MESH (Medical Subject Headings) were utilized. The dependent terms used in the search were Salmonella food poisoning/“intoxicación alimentaria por Salmonella y Salmonella enterica”. The independent variables associated with drug resistance were Microbial/“facorresistencia microbiana” and Microbial sensitivity tests/“pruebas de sensibilidad microbiana” [30].

To search for subjects concerning meat or meat products the terms meat products/“productos de carne” (in singular and plural), poultry products/“productos avícolas”, food safety/“análisis de peligros y puntos críticos de control”, “inocuidad de los alimentos”, food contamination/“contaminación de alimentos”, foodborne diseases/“enfermedades transmitidas por los alimentos”, fast foods/“comidas rápidas” and raw foods/“alimentos crudos” were employed [30].

2.2. Inclusion and Exclusion Criteria

Experimental studies performed between 1996 and 2019 were included, encompassing the year when the international observation and monitoring of antimicrobial resistance programs was initiated. English and Spanish were the selected languages, as illustrated by the search equations [30].

In the selected articles, isolates must have been from meat or meat products collected at retail or intended for the same purpose. The selected article should describe Salmonella spp., isolates and the non-typhoidal serotypes identification [30].
For the analysis, selected articles were classified according to the antimicrobial susceptibility detection method into the disc diffusion method and minimum inhibitory concentration (MIC). After verifying breakpoints and references, articles with interpretive criteria or isolate frequencies of resistance to antimicrobial agents were included [30].

Articles where title and abstract were not related to the topic of interest were excluded. Correspondingly, food outbreak studies were also excluded since, for many of these studies, it was difficult to identify source of contamination by *Salmonella* spp. Additionally, articles involving isolates from biological collections were not included as there was no clarity regarding sample type, years of preservation, or origin [30].

### 2.3. Extraction and Data Registry

Article assembled information included country, type of meat or meat product, the method used (disc diffusion or MIC), breakpoints, the standard used or implemented (national or international), and susceptibility test results [30].

Selected articles described the susceptibility to different families of antibiotics belonging to the following classes: penicillin, combination β-lactamase inhibitors, cephems, monobactams, aminoglycosides, quinolones, fluoroquinolones, folate pathway inhibitors, phenols, nitrofurans, and tetracyclines [30].

### 2.4. Data Analysis

Data analysis focused on three different aspects. First, in the descriptive phase, the following items were considered: sample country of origin, animal species of the meat or meat product, identified serotypes, antimicrobial susceptibility test used, and standard employed. Second, articles were classified according to the method used (disc diffusion or MIC) for each group [30].

Third, the percentage prevalence for each serotype was calculated as follows:

\[
\text{Calculated frequency } \% = \frac{\text{Number of isolates reported}}{\text{total number of isolates}} \times 100.
\]

The analysis was performed according to the antimicrobial susceptibility assessment method described in each study and the serovar-ties were evaluated.

Some studies used the evaluation of antimicrobial susceptibility standard for isolates of animal origin. Since 2013 the M31 version was modified into the VET01-S3 (2013). Subsequently, from June 2018, the VET 01-04 (2018) was modified into the VET08. Therefore, to maintain the article’s original information, the names of the standards were kept as published [30].

### 3. Results

#### 3.1. Number of Articles, Countries, and Standard

A total of 3802 articles were associated according to registered equations, of which 1141 were preselected (30%). Only 4% (48/1141) complied 100% with defined inclusion and exclusion criteria (Figure 1 and Table 1). The distribution of selected articles by country was as follows: China with seven studies (15%), followed by Egypt and Vietnam with six articles each (13%), South Korea with four papers (8%), Brazil, Canada, Colombia, Spain, United States of America, Iran, Malaysia, and Thailand with two articles each (4%) and, last, Greece, Italy, Mexico, Portugal, Rumania, Senegal, Singapore, Turkey, and Venezuela with one article each (2%).

The CLSI standards were referenced in 45/48 (93.8%) articles. Thirty-seven (82.2%) of them used the M100 standard, corresponding to the Performance Standard for Antimicrobial Susceptibility Testing. Seven (15.6%) used the M31 standard for disc diffusion and dilution susceptibility Performance Standard for Antimicrobial Disc and Dilution Susceptibility Tests for Bacteria Isolated from Animals, and one (2.2%) used both M100 and M31. On the other hand, for the remaining 3/48 (6.3%) articles, interpretation criteria established by NARMS and CIPARS monitoring programs were used, as well as the international
organizations “Comité de l’antibiogramme de la société française de microbiologie” (CA-SFM), and the European Committee on Antimicrobial Susceptibility Testing—EUCAST (Table 1).

Figure 1. Strategy for selection of eligible articles. Flowchart made based on [31,32].
Table 1. Standards used to define the interpretation criteria for antimicrobial susceptibility tests in selected articles.

| Standards Used in the Articles | Antimicrobial Susceptibility Test |
|-------------------------------|----------------------------------|
| Ref.                          | CLSI, M100-S9 [33]               | x |
|                               | CLSI, M100-S11 [34]              | x |
|                               | CLSI, M100-S13 [35]              | x |
|                               | CLSI, M100-S15 [36]              | x |
|                               | CLSI, M100-S16 [37]              | x |
|                               | CLSI, M100-S18 [38]              | x |
|                               | CLSI, M100-S19 [39]              | x |
|                               | CLSI, M100-S20 [40]              | x |
|                               | CLSI, M100-S21 [42]              | x |
|                               | CLSI, M100-S22 [43]              | x |
|                               | CLSI, M100-S23 [44]              | x |
|                               | CLSI, M100-S24 [45]              | x |
|                               | CLSI, M100-S25 [46]              | x |
|                               | CLSI, M100-S28 [47]              | x |
|                               | CLSI, M100-S29 [48]              | x |
|                               | CASFM [49]                       | x |
|                               | EUCAST NARMS [50]                | x |
|                               | NARMS (It Was Not Cited by Authors); CIPARS [51] | x |
|                               | CLSI, M31-S1 [52]                | x |
|                               | CLSI, M31-A2 [53]                | x |
|                               | CLSI, M31-A3 [54]                | x |
|                               | MIC Disc Diffusion               | x |

Legend: x = Present; X = Absent
Table 1. Cont.

| Ref. | CLSI, M100-S9 [33] | CLSI, M100-S11 [34] | CLSI, M100-S13 [35] | CLSI, M100-S15 [36] | CLSI, M100-S16 [37] | CLSI, M100-S17 [38] | CLSI, M100-S19 [40] | CLSI, M100-S20 [41] | CLSI, M100-S21 [42] | CLSI, M100-S22 [43] | CLSI, M100-S23 [44] | CLSI, M100-S24 [45] | CLSI, M100-S25 [46] | CLSI, M100-S28 [47] | CASFM [48] | EUCAST [49] | NARMS (it Was Not Cited by Authors); CIPARS [51] | CLSI, M31-S1 [52] | CLSI, M31-A2 [53] | CLSI, M31-A3 [54] | MIC | Disc Diffusion |
|------|-------------------|---------------------|----------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|---------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|
| [92] | ** X X**          |                     |                      |                   |                   |                   |                   |                   |                   |                   |                   |                   |                   |                   |                     |                     |                   |                   |                   |                   |                   | ** X X**          |
| [93] |                   |                     |                      |                   |                   |                   |                   |                   |                   |                   |                   |                   |                   |                   |                     |                     |                   |                   |                   |                   |                   | ** X X**          |
| [94] |                   |                     |                      |                   |                   |                   |                   |                   |                   |                   |                   |                   |                   |                   |                     |                     |                   |                   |                   |                   |                   | ** X X**          |
| [95] |                   |                     |                      |                   |                   |                   |                   |                   |                   |                   |                   |                   |                   |                   |                     |                     |                   |                   |                   |                   |                   | ** X X**          |
| [96] |                   |                     |                      |                   |                   |                   |                   |                   |                   |                   |                   |                   |                   |                   |                     |                     |                   |                   |                   |                   |                   | ** X X**          |
| [97] |                   |                     |                      |                   |                   |                   |                   |                   |                   |                   |                   |                   |                   |                   |                     |                     |                   |                   |                   |                   |                   | ** X X**          |

* The authors referred to the standard “CLSI, M100-S2”, and analysis for the present study used the CLSI, M100-S23. ** Authors made reference to the CLSI standard, 2013. However, it was not included in their references. Therefore, it was assumed the CLSI, M100-S23 standard was used. X means that standard or susceptibility test cited in the top of table was or were used in each study reference.
3.2. Reported Salmonella Enterica Serotypes

Out of the 48 analyzed studies, 211 serotypes were reported, of which 16.6% (35/211) were described five or more times (Figure 1), while the remaining 83.4% (176/211) were only reported in one to three studies (Table S1).

3.3. Analysis of Antibiotic Concentration Used According to Each Method

In the selected articles, the most common methodology employed was disc diffusion with 68.8% (33/48), followed by MIC 22.9% (11/48) and 8.3% (4/48), which used both methodologies (Table 1). For articles that described using MIC, in 7/15 (46.6%) of them antibiotic concentrations were not indicated [60,62,66,82,84,86,93]. Information regarding the remaining seven articles is displayed in Table S2.

3.4. Breakpoints and Interpretative Criteria for Antimicrobial Susceptibility Testing

Articles using MIC according to CLSI guidelines analyzed the results based on the standard issued between 2001 and 2014. Studies that implemented disc diffusion interpreted the results according to the standard published between 1999 and 2018 (Table 1).

3.5. Resistance to Salmonella Serotypes Assayed by the MIC Method

Six (54.5%) studies employing the MIC methodology presented results as a pattern of resistance, gathered as the sequence of antibiotics to which the microorganism was resistant, and five (45.5%) displayed the results as prevalence percentage for each antibiotic.

The number of articles that presented resistance as a percentage five, of which the work by Clemente et al., (2013) based its analysis on EUCAST (2012) clinical and epidemiological breakpoints. The highest resistance was for TET, SUL, AMP, and STR. Nhung et al., (2018) used CLSI M100-S24 clinical breakpoints, and the highest resistance percentage was for the Tetracyclines, Quinolones, Penicillins, and Folate pathway inhibitors. The resistance results for the remaining three articles are displayed in Table 2. As observed in one of them, prevalence differed from the one calculated by us (based on data) to the one published by the authors [80]. Additionally, in AMP, AMC, CIP, NAL, SXT, and TET, the calculated or reported prevalence was greater than 100 due to inconsistencies in some articles. The number of resistant isolates was higher than the number of isolates obtained as described by the authors.

In articles presenting resistance patterns, the number of total isolates was 113, classified in 18 serotypes, where Heidelberg was the predominant one. Likewise, sixty different resistance patterns were described according to the antibiotics of interest in the present work. The serotype displaying the highest number of resistances to antibiotics (10 resistances) was Bredeney [60]. The classes to which it presented the highest resistance were the aminoglycosides (GEN, TOB, AMK, KAN, STR) and cephems (CFZ, CEP, CTX, CRO, FOX, CXM, CAZ) (Table 3 and Table S3).
Table 2. *Salmonella* spp. antimicrobial agent frequency of resistance as determined by MIC.

| Antibiotic Agent | Prevalence Analysis | Typhimurium * [64,66,80] | Enteritidis * [66,80] | Agona [80] | Heidelberg [66] | Indiana [66] | Infantis [66] | Kentucky [64] | Mbndaka [64] | Thompson [80] |
|------------------|---------------------|--------------------------|------------------------|------------|--------------|--------------|--------------|--------------|--------------|--------------|
| AMP N° isolates  | 148 268             | 46 16                    | 114 19                 | 24 3       | 55           |              |              |              |              |              |
| N° resistant isolates | 97 185         | 22 16                    | 114 19                 | 24 3       | 55           |              |              |              |              |              |
| Reported frequency (%) | 47.8 100 | 100 92.1                | 31.6 ND                | 5 ND       | 66           |              |              |              |              |              |
| Calculated frequency (%) | 65.5 69.0 | 69.0 92.1               | 31.6 20.8              | 33.3 ND    | 76.7         |              |              |              |              |              |
| AMC N° isolates  | 148 268             | 46 16                    | 114 19                 | 24 3       | 55           |              |              |              |              |              |
| N° resistant isolates | 58 111        | 16 ND                    | 91 ND                  | 5 1        | 56           |              |              |              |              |              |
| Reported frequency (%) | 34.8 0      | 79.8 ND                  | ND ND                  | ND ND      | 65.1         |              |              |              |              |              |
| Calculated frequency (%) | 39.2 41.4 | 79.8 ND                  | ND ND                  | ND ND      | 65.1         |              |              |              |              |              |
| CRO N° isolates  | 148 268             | 46 16                    | 114 19                 | 24 3       | 55           |              |              |              |              |              |
| N° resistant isolates | 12 45        | 6 12                    | 73 0                   | 0 ND       | 29           |              |              |              |              |              |
| Reported frequency (%) | 15.4 75   | 75 64                   | ND ND                  | ND ND      | 34.5         |              |              |              |              |              |
| Calculated frequency (%) | 8.1 16.8  | 13.0 ND                 | 75 64                  | ND ND      | 34.5         |              |              |              |              |              |
| FOX N° isolates  | 148 268             | 46 16                    | 114 19                 | 24 3       | 55           |              |              |              |              |              |
| N° resistant isolates | 22 71       | 8 4                     | 42 0                   | 3 1        | 28           |              |              |              |              |              |
| Reported frequency (%) | 17.4 25    | 37 ND                   | ND ND                  | ND ND      | 32.6         |              |              |              |              |              |
| Calculated frequency (%) | 14.9 26.5   | 17.4 25                 | 37.0 ND                | 20.8 ND    | 50.9         |              |              |              |              |              |
| GEN N° isolates  | 148 268             | 46 16                    | 114 19                 | 24 3       | 55           |              |              |              |              |              |
| N° resistant isolates | 40 81       | 6 0                     | 93 5                   | ND ND      | 44           |              |              |              |              |              |
| Reported frequency (%) | 13.0 0     | 0 8.1                   | 26.3 ND                | ND ND      | 51.2         |              |              |              |              |              |
| Calculated frequency (%) | 27.0 30.2   | 13.0 0                  | 8.1 26.3               | ND ND      | 51.2         |              |              |              |              |              |
| STR N° isolates  | 148 268             | 46 16                    | 114 19                 | 24 3       | 55           |              |              |              |              |              |
| N° resistant isolates | 78 155      | 14 16                   | 83 18                  | 12 1       | 18           |              |              |              |              |              |
| Reported frequency (%) | 30.4 100    | 73.5 94.7               | ND ND                  | ND ND      | 20.9         |              |              |              |              |              |
| Calculated frequency (%) | 52.7 57.8  | 52.7 100                | 72.8 94.7              | 50.0 33    | 32.7         |              |              |              |              |              |
| CIP N° isolates  | 148 268             | 46 16                    | 114 19                 | 24 3       | 55           |              |              |              |              |              |
| N° resistant isolates | 22 81       | 10 93                   | 0 ND                   | ND ND      | 8            |              |              |              |              |              |
| Reported frequency (%) | 14.9 11.9  | 21.7 81.6               | ND 0                   | ND ND      | 9.3          |              |              |              |              |              |
| Calculated frequency (%) | 14.9 11.9   | 21.7 81.6               | ND 0                   | ND ND      | 9.3          |              |              |              |              |              |
| NAL N° isolates  | 148 268             | 46 16                    | 114 19                 | 24 3       | 55           |              |              |              |              |              |
| N° resistant isolates | 81 275      | 23 2                    | 106 3                  | ND ND      | 39           |              |              |              |              |              |
| Reported frequency (%) | 50.0 12.5   | 93 15.8                 | ND ND                  | ND ND      | 45.4         |              |              |              |              |              |
| Calculated frequency (%) | 54.7 102.6  | 54.7 102.6              | 93.0 15.8              | 93.0 ND    | 70.9         |              |              |              |              |              |
| SXT N° isolates  | 148 268             | 46 16                    | 114 19                 | 24 3       | 55           |              |              |              |              |              |
| N° resistant isolates | 70 123      | 23 0                    | 105 2                  | 15 0       | 70           |              |              |              |              |              |
| Reported frequency (%) | 50.0 0     | 92.1 10.5               | ND ND                  | ND ND      | 60.9         |              |              |              |              |              |
| Calculated frequency (%) | 47.3 45.9  | 47.3 45.9               | 92.1 10.5              | 92.1 10.5  | 109.1        |              |              |              |              |              |
| TET N° isolates  | 148 268             | 46 16                    | 114 19                 | 24 3       | 55           |              |              |              |              |              |
| N° resistant isolates | 123 191     | 30 0                    | 104 0                  | 15 0       | 70           |              |              |              |              |              |
| Reported frequency (%) | 65.2 0     | 91.2 ND                 | ND ND                  | ND ND      | 81.4         |              |              |              |              |              |
| Calculated frequency (%) | 83.1 71.3  | 83.1 71.3               | 91.2 ND                | ND ND      | 127.3        |              |              |              |              |              |

No. isolates, number of isolates; No. resistant, number of resistant isolates; F. Reported (%), frequency reported; F. Calculated (%), frequency calculated. The box highlighted in yellow are the calculated values that exceeded 100%, while the boxes highlighted in gray indicate the values that could not be calculated. * For Enteritidis and Typhimurium serovars, frequency was calculated based on the sum of reported isolates in the articles.
Table 3. Patterns of multidrug resistant *Salmonella* spp. as determined by MIC.

| Ref. | Pattern | Serovar/ (Total Serovar) | Total Isolates with the Pattern | % Isolates with the Pattern |
|------|---------|--------------------------|-------------------------------|-----------------------------|
| [67] | AMP SXTTET | Rissen (1) | 1 | 100 |
|      |         | Worthington (1) | 1 | 100 |
| [91] | AMC CEP GEN KAN STR | Ouakam (1) | 1 | 100 |
|      |         | Tennessee (7) | 2 | 29 |
| [60] | AMP AMC CEP FOX | Agona (3) | 3 | 100 |
|      |         | Heidelberg (13) | 2 | 15 |
|      |         | Litchfield (2) | 2 | 100 |
| [91] | AMP AMC CEP GEN KAN STR | Anatum (1) | 1 | 100 |
|      |         | Tennessee (7) | 4 | 57 |
| [91] | AMP AMC CEP GEN KAN STR NAL TET | Enteritidis (3) | 1 | 33 |
|      |         | Saintpaul (3) | 1 | 33 |
| [91] | AMP AMC CEP GEN KAN STR TET | Montevideo (1) | 1 | 100 |
|      |         | Anatum_var-15+ (1) | 1 | 100 |
|      |         | Saintpaul (3) | 2 | 67 |
|      |         | Seftenberg (4) | 2 | 50 |
| [67] | AMP AMC CRO FOX | Heidelberg (13) | 11 | 85 |
|      |         | LROUGH-0r:1,2 (1) | 1 | 100 |
|      |         | Infantis (4) | 1 | 25 |
|      |         | Kentucky (2) | 2 | 100 |
| [21] | AMP AMC CRO FOX CRO FOX CPD ATM GEN KAN STR CIP NAL SXT CHL TET | Typhimurium (4) | 1 | 25 |
|      |         | Enteritidis (3) | 1 | 33 |
| [91] | AMP AMC GEN KAN STR | Seftenberg (4) | 1 | 25 |
|      |         | Tennessee (7) | 1 | 14 |
| [60,91] | AMP CEP GEN | Enteritidis (3) | 1 | 33 |
|      |         | Seftenberg (4) | 1 | 25 |
| [21] | AMP KAN NAL SXT CHL TET | Typhimurium (4) | 2 | 50 |
|      |         | Typhimurium (4) | 1 | 25 |
| [86] | GEN TOB AMK CIP SXT | Enteritidis | ND | 0 |
|      |         | Kentucky | ND | 0 |
| [84] | STR CIP NAL SUL TET | Infantis (4) | 3 | 75 |

3.6. *Salmonella* Serotype Resistance Assayed by the Disc Diffusion Method

Resistance and multi-resistance analysis were reported on 31/33 (93.9%) of the studies. For 2/33 (6.1%), isolate, pattern or resistance percentage, and isolate origin were not related [63,68]. On the other hand, of the 31 articles analyzed, 6 (19.4%) presented the results as resistance percentage, 19 (61.3%) as the pattern of resistance, and 6 (19.4%) as the pattern and resistance percentage.

The articles that presented resistance results as the percentage of prevalence were 12/31 (39%), of which Valdezate et al. (2007) showed resistance percentage to the Enteritidis and Typhimurium; serotypes, describing the highest resistance to spectinomycin with 99% (95/96) and 87% (46/53), respectively, followed by NAL 40.6% (39/96) for Enteritidis and TET with 71.7% (38/53) for Typhimurium. The remaining 11 studies are displayed Table 4 and Table S4, where resistance percentage calculated for reported serotypes in more than one study appear (the ones with only one serotype are in Table S5). It is noteworthy that in various studies [17,83,92], some of the reported prevalences differ from those calculated by us. Additionally, the serotype most frequently found was Typhimurium (8/11 (72.7%)), and the most frequent resistance for this serotype was tetracycline.

Multi-resistance pattern analysis allowed the identification of 692 isolates, of which 444 presented different patterns (Table S6). The remaining 248 isolates were grouped in 27 different patterns (Table 5). The profile AMP SXT STR TET was the most prevalent resistance pattern in these isolates. Additionally, Enteritidis and Typhimurium serotypes
displayed a resistance pattern with the greatest number of antibiotic classes: penicillins (AMP), β-lactamase inhibitors (AMC), cephems (CTX CRO FOX CPD), monobactams (ATM), aminoglycosides (GEN KAN STR), fluoroquinolones (CIP), quinolones (NAL), folate pathway inhibitors (SXT), phenolic compounds (CHL), and nitrofurans (TET).

Table 4. Frequency of *Salmonella* isolates resistant to antimicrobials as determined by disc diffusion.

| Serovar   | Number of Isolates | AMP | GEN | AMK | KAN | STR | CIP | OFX | NAL | SXT | TMP | SUL | CHL | TET |
|-----------|---------------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Agona     | 71                  | 22.5| 100 | 16.1| 1.8 | 91.1| 19.6| 17.9| 41.1| 89.3| 48.2|     |     |     |
| Anatum    | 5                   | 100 | 20.0| 20.0| 60.0| 40.0|     |     |     |     |     |     |     |     |
|           | 7                   | 100 |     |     |     | 40.0|     |     |     |     |     |     |     |     |
|           | 3                   |     |     |     |     | 57.1|     |     |     |     |     |     |     |     |
| Corvallis | 1                   |     |     |     |     |     |     |     |     |     |     |     |     |     |
|           | 46                  |     |     |     |     |     |     |     |     |     |     |     |     |     |
|           | 3                   |     |     |     |     |     |     |     |     |     |     |     |     |     |
| Derby     | 11                  | 100 | 45.5|     |     |     |     |     |     |     |     |     |     |     |
|           | 1                   |     | 100 |     |     |     |     |     |     |     |     |     |     |     |
|           | 1                   |     |     |     |     |     |     |     |     |     |     |     |     |     |
|           | 75                  |     |     |     |     |     |     |     |     |     |     |     |     |     |
|           | 79                  |     |     |     |     |     |     |     |     |     |     |     |     |     |
| Enteritidis | 6                  | 100 |     |     |     |     |     |     |     |     |     |     |     |     |
|           | 6                   |     |     |     |     |     |     |     |     |     |     |     |     |     |
|           | 27                  |     |     |     |     |     |     |     |     |     |     |     |     |     |
|           | 30                  |     |     |     |     |     |     |     |     |     |     |     |     |     |
|           | 8                   |     |     |     |     |     |     |     |     |     |     |     |     |     |
|           | 7                   |     |     |     |     |     |     |     |     |     |     |     |     |     |
| Hadar     | 6                   | 16.7|     |     |     |     |     |     |     |     |     |     |     |     |
|           | 8                   | 25.0|     |     |     |     |     |     |     |     |     |     |     |     |
|           | 31                  | 25.8|     |     |     |     |     |     |     |     |     |     |     |     |
|           | 6                   | 16.7|     |     |     |     |     |     |     |     |     |     |     |     |
| Indiana   | 28                  | 71.4| 14.3|     |     |     |     |     |     |     |     |     |     |     |
|           | 5                   |     |     |     |     |     |     |     |     |     |     |     |     |     |
|           | 4                   |     |     |     |     |     |     |     |     |     |     |     |     |     |
| Kentucky | 27                  | 44.4|     |     |     |     |     |     |     |     |     |     |     |     |
|           | 2                   |     |     |     |     |     |     |     |     |     |     |     |     |     |
|           | 38                  |     |     |     |     |     |     |     |     |     |     |     |     |     |
| London    | 57                  | 61.4| 57.9|     |     |     |     |     |     |     |     |     |     |     |
|           | 20                  | 50.0| 25.0| 5.0  |     |     |     |     |     |     |     |     |     |     |
| Mbandaka | 3                   |     |     |     |     |     |     |     |     |     |     |     |     |     |
|           | 34                  |     |     |     |     |     |     |     |     |     |     |     |     |     |
| Muenster | 12                  | 50.0| 20.0| 20.0|     |     |     |     |     |     |     |     |     |     |
|           | 10                  |     |     |     |     |     |     |     |     |     |     |     |     |     |
| Panama   | 12                  | 83.3|     |     |     |     |     |     |     |     |     |     |     |     |
|           | 8                   |     |     |     |     |     |     |     |     |     |     |     |     |     |
|           | 10                  |     |     |     |     |     |     |     |     |     |     |     |     |     |
| Rissen   | 6                   | 100 |     |     |     |     |     |     |     |     |     |     |     |     |
|           | 81                  |     |     |     |     |     |     |     |     |     |     |     |     |     |
|           | 18                  |     |     |     |     |     |     |     |     |     |     |     |     |     |
| Schwarzengrund | 2 | 100 |     |     |     |     |     |     |     |     |     |     |     |     |
|           | 7                   |     |     |     |     |     |     |     |     |     |     |     |     |     |
| Stanley  | 6                   | 83.3| 33.3| 33.3| 33.3|     |     |     |     |     |     |     |     |     |
|           | 3                   |     |     |     |     |     |     |     |     |     |     |     |     |     |
| Thompson | 85                  | 2.4 | 31.5| 31.5|     |     |     |     |     |     |     |     |     |     |
|           | 54                  |     |     |     |     |     |     |     |     |     |     |     |     |     |
|           | 3                   |     |     |     |     |     |     |     |     |     |     |     |     |     |
| Typhimurium | 8                | 62.5| 12.5|     |     |     |     |     |     |     |     |     |     |     |
|           | 3                   |     |     |     |     |     |     |     |     |     |     |     |     |     |
|           | 14                  |     |     |     |     |     |     |     |     |     |     |     |     |     |
|           | 5                   |     |     |     |     |     |     |     |     |     |     |     |     |     |
|           | 84                  |     |     |     |     |     |     |     |     |     |     |     |     |     |
|           | 22                  |     |     |     |     |     |     |     |     |     |     |     |     |     |
Table 5. Patterns of multidrug resistant *Salmonella* serovar as determined by disc diffusion.

| Ref. | Pattern | Serovar/ (Total Serovar) | Total Isolates with the Pattern | % of Isolates with the Pattern |
|------|---------|--------------------------|---------------------------------|-------------------------------|
| [71] [69] | AMC CEP NAL | Typhimurium (34) | 1 | 3 |
| | | Montevideo (3) | 1 | 33 |
| [70] | AMP CEP NAL TET | Hadar (1) | 1 | 100 |
| | | Tshiongwe (1) | 1 | 100 |
| [70] [21] | AMP GEN KAN STR CIP SXT TET | Enteritidis (25) | 2 | 8 |
| | | Infantis (4) | 1 | 25 |
| [74] | AMP GEN NAL SXT TET | Anatum (20) | 1 | 5 |
| | | Typhimurium (34) | 1 | 3 |
| [74] | AMP GEN STR SXT CHL TET | Derby (70) | 1 | 1 |
| | | London (3) | 1 | 33 |
| | | Panama (9) | 1 | 11 |
| [89] | | Typhimurium (34) | 1 | 3 |
| [74] [21] | AMP KAN STR NAL SXT CHL TET | Meleagrisidis (9) | 1 | 11 |
| | | Typhimurium (34) | 1 | 3 |
| [56] | AMP NAL CHL | Kentucky (7) | 2 | 29 |
| | | Schwarzengrund (7) | 6 | 86 |
| [87] | AMP NAL CHL TET | Albany (5) | 1 | 20 |
| | | Anatum (20) | 1 | 5 |
| | | Derby (70) | 1 | 1 |
| [76] | AMP NAL SXT | Enteritidis (25) | 1 | 4 |
| | | Kentucky (7) | 4 | 57 |
| | | Muenster (6) | 6 | 100 |
| | | Virchow (2) | 2 | 100 |
| [87] | AMP NAL SXT CHL | Schwarzengrund (7) | 1 | 14 |
| | | Anatum (20) | 1 | 5 |
| | | Infantis (4) | 1 | 25 |
| [74] | AMP NAL SXT CHL TET | Derby (70) | 1 | 1 |
| | | Infantis (4) | 1 | 25 |
| | | Albany (5) | 4 | 80 |
| | | Anatum (20) | 2 | 10 |
| | | Panama (9) | 1 | 11 |
| | | Rissen (4) | 1 | 17 |
| | | Brancaster (3) | 1 | 33 |
| | | Stanley (8) | 1 | 13 |
| [87] | AMP NAL SXT TET | Agona (3) | 1 | 33 |
| | | Anatum (20) | 1 | 5 |
| [74] | AMP NAL SXT TET | Derby (70) | 1 | 1 |
| | | Typhimurium (34) | 1 | 3 |
| [74] | AMP NAL TET | Derby (70) | 4 | 6 |
| | | Rissen (4) | 1 | 17 |
| | | S.4.5.12:i; – (2) | 2 | 100 |
| | | Stanley (8) | 3 | 38 |
| [81] | | Enteritidis (25) | 1 | 4 |
| | | Typhimurium (34) | 2 | 6 |
| [58] | | Anatum | ND | ND |
| [70] | | Typhimurium (34) | 2 | 6 |
| [72] | AMP STR NAL SXT TET | Anatum (20) | 1 | 5 |
| | | Derby (70) | 2 | 3 |
| [85] | | Derby (70) | 2 | 3 |
Table 5. Cont.

| Ref. | Pattern          | Serovar/ (Total Serovar) | Total Isolates with the Pattern | % of Isolates with the Pattern |
|------|------------------|--------------------------|---------------------------------|-------------------------------|
| [85] | AMP STR SXT CHL TET | Meleagris (9)            | 2                               | 22                            |
| [74] |                  | Typhimurium (34)         | 1                               | 3                             |
|      | Derby (70)       | 1                        |                                 |                               |
|      | Rissen (4)       | 1                        |                                 |                               |
|      | Give (1)         | 1                        |                                 |                               |
|      | Typhimurium (34) | 1                        |                                 |                               |
| [89] |                  | Agona (3)                | 1                               | 33                            |
| [72] | AMP STR SXT TET  | Brandenburg (1)          | 1                               | 100                           |
| [74] |                  | Saintpaul (2)            | 1                               | 50                            |
|      | Derby (70)       | 1                        |                                 |                               |
|      | Derby (70)       | 7                        | 10                              |
|      | Typhimurium (34) | 4                        | 12                              |
| [85] | AMP STR SXT TET  | Derby (70)               | 7                               | 10                            |
| [74] |                  | Typhimurium (34)         | 4                               | 12                            |
|      | Derby (70)       | 7                        | 10                              |
|      | Meleagris (9)    | 1                        | 11                              |
|      | Newport (5)      | 1                        | 20                              |
|      | Derby (70)       | 7                        | 10                              |
| [89] | Typhimurium (34) | 4                        | 12                              |
| [70] |                  | Bredeney (3)             | 1                               | 33                            |
| [74] | AMP SXT CHL TET  | Typhimurium (34)         | 3                               | 9                             |
| [87] |                  | Anatum (20)              | 1                               | 5                             |
| [81] |                  | Panama (9)               | 7                               | 78                            |
| [95] | AMP SXT TET      | Bovismoribicans (1)      | 1                               | 100                           |
|      | Brancaster (3)   | 1                        | 33                              |
|      | Stanley (8)      | 4                        | 50                              |
|      | Typhimurium (34) | 3                        | 9                               |
| [77] | AMP SXT TET      | Agona (3)                | 1                               | 33                            |
|      | Anatum (20)      | 5                        | 25                              |
|      | Bredeney (3)     | 2                        | 67                              |
|      | Coeln (1)        | 1                        | 100                             |
|      | Derby (70)       | 8                        | 11                              |
|      | London (3)       | 1                        | 33                              |
|      | Senftenberg (1)  | 1                        | 100                             |
|      | Typhimurium (34) | 1                        | 3                               |
| [85] |                  | Derby (70)               | 8                               | 11                            |
| [74] |                  | Derby (70)               | 8                               | 11                            |
| [87] |                  | Anatum (20)              | 5                               | 25                            |
|      | Rissen (4)       | 1                        | 17                              |
| [71] | CEP STR NAL      | Enteritidis (25)         | 4                               | 16                            |
| [69] |                  | Newport (5)              | 1                               | 20                            |
|      | Enteritidis (25) | 4                        | 16                              |
|      | Montevideo (3)   | 2                        | 67                              |
| [70] | KAN STR NAL TET  | Blockey (4)              | 4                               | 100                           |
| [81] |                  | Enteritidis (25)         | 3                               | 12                            |
|      | Newport (5)      | 2                        | 40                              |
| [85] | NAL CHL TET      | Derby (70)               | 1                               | 1                             |
| [87] |                  | Typhimurium (34)         | 4                               | 12                            |
|      | Indiana (1)      | 1                        | 100                             |
| [74] | NAL SXT TET      | Infantis (4)             | 1                               | 25                            |
| [81] |                  | Meleagris (9)            | 5                               | 56                            |
|      | Thompson (1)     | 1                        | 100                             |
3.7. Serotype Resistance Determined by MIC and Disc Diffusion Methods

The total number of articles using two methods for antimicrobial susceptibility evaluation was 4/48 (8.3%), of which three presented results as resistance pattern and one presented the results as a percentage of prevalence.

For one article [78], the highest resistance (94%) was observed for the Heidelberg serotype to TET. Additionally, when comparing the reported percentage in the article and the calculations according to the data published by the authors, an inconsistency was observed for AMC, for the serotypes Enteritidis (Reported: 37.31 and Calculated: 7.5), and for Typhimurium (Reported: 2.50 and Calculated: 5).

Observed multi-resistance patterns are displayed in Table 6. The serotype with the highest resistance was Heidelberg, which was resistant to six classes of antibiotics and nine antibiotics (AMP AMC CFZ CTX CRO FOX CIP NAL TET), where TET was the antibiotic presenting resistance more frequently in isolates.

### Table 5. Cont.

| Ref. | Pattern | Serovar/ (Total Serovar) | Total Isolates with the Pattern | % of Isolates with the Pattern |
|------|---------|--------------------------|--------------------------------|-------------------------------|
| [71] | STR NAL TET | Enteritidis (25) | 5 | 20 |
| [72] | STR SUL TET | Anatum (20) | 1 | 5 |
| [81] | STR SXT CHL TET | Reading (1) | 1 | 100 |
| [58] | STR SXT SUL TET | Enteritidis (25) | 5 | 20 |
| [72] | STR SXT SUL TET | Newport (5) | 1 | 20 |
| [58] | STR SXT SUL TET | Hadar | ND | ND |

### Table 6. Salmonella serovar patterns of multidrug resistance as determined by disc diffusion and MIC.

| Reference | Multiresistance Patterns | Serovar (Total Isolates) | Total Isolates with the Multiresistance Pattern | % Frequency of Multiresistance Pattern |
|-----------|--------------------------|--------------------------|-----------------------------------------------|---------------------------------------|
| [62]      | AMP CTX SXT              | Enteritidis (3)          | 1                                             | 33.3                                  |
| [26]      | CIP NAL TET              | Heidelberg (11)          | 2                                             | 25.0                                  |
| [82]      | AMP AMC CFZ CEP CTX TET  | Bareilly (1)             | 1                                             | 100                                   |
| [62]      | AMP CFZ CTX ATM CIP SXT  | Heidelberg (11)          | 2                                             | 18.2                                  |
| [82]      | AMP CFZ CEP CTX STR NAL TET | Infantis (8)          | 8                                             | 100                                   |
| [82]      | AMP CFZ CEP CTX GEN STR NAL TET | Enteritidis (3) | 1 | 33.3 |
| [26]      | AMP AMC CFZ CTX CRO FOX NAL TET | Heidelberg (11) | 3 | 27.3 |
| [82]      | AMP AMC CFZ CEP CTX STR NAL TET | Virchow (16)         | 7                                             | 43.8                                  |
| [82]      | AMP AMC CFZ CEP CTX GEN STR NAL TET | Enteritidis (3) | 1 | 33.3 |
| [26]      | AMP AMC CFZ CTX CRO FOX CIP NAL TET | Heidelberg (11) | 2 | 18.2 |
4. Discussion

4.1. Number of Articles, Countries, and Standard

A total of 48 articles were included in this study after eliminating those based on exclusion criteria (Figure 1), where the most representative countries were China, Egypt, and Vietnam. On the other hand, the most implemented standard was the CLSI M100 (Table 1). However, the Clemente et al., (2013) study used ECOFFs clinical and epidemiological cut-off points for bacterial resistance analysis.

4.2. Salmonella Enterica Reported Serotypes

Among the 48 studies selected, 211 serotypes were identified. This diversity was due to regional differences, environmental factors, origin, and food production practices. These factors favour the specific serovars found by influencing survival or transmission routes [98].

The most frequently recognized serovars were four (Figure 2). Between 2004 and 2016, Typhimurium caused many of the clinical infections worldwide [98]. It is also one of the most common causative agents for invasive salmonellosis by non-typhoid serotypes [99]. This serotype also affects livestock production systems and has been isolated in poultry, pigs, and cattle, this latter being the principal carrier [100].

Figure 2. Frequency of serovars described in more than five studies. Abbreviations: Bovismor, Bovismorbificans; Bra, Braenderup; Ind, Indiana; Pan, Panama; Mba, Mbandaka; Mon, Montevideo; Thom, Thompson; Vir, Virchow; Wel, Weltevreden.

The second most frequent serotype was Enteritidis (Figure 2), the principal agent causing clinical salmonellosis reported between 2004 and 2016 in Brazil, Canada, Europe, China, the United States of America, Tunisia, and Thailand [98]. S. enteritidis transmission to humans occurs through poorly cooked chicken, contaminated raw eggs, or products prepared with contaminated eggs. In poultry, this serovar can remain in the reproductive system tissue. Hence, it is necessary to control this microorganism during poultry production [101,102].

S. Anatum was the third serotype reported (Figure 2). This serotype was described first in 2005 as the ninth serotype resulting in human illnesses on the European Food Safety Authority report of tendencies and zoonosis, zoonotic agents, and outbreaks associated with food. S. Anatum is one of the serotypes responsible between 2015 and 2017 for an increase in human infections in Taiwan. Many of its isolates are multiresistant and prevalent in animal species destined for human consumption [103].

The fourth serotype reported and the most frequently found in selected articles was S. Derby (Figure 2). This serotype has been described in pork production, where pork meat
is the route of transmission in some human outbreaks [104]. It has also been frequently reported in pig slaughter, surviving in first minute during the scalding process [105].

The remaining 64 serotypes appear in Figure 2, Table S1; 16/64 (25%) were found in at least ten or more selected articles. These 16 serotypes had been previously notified by NARMS (1997–2015) [106–125], EFSA (2004–2015) [106–125] and EFSA (2004–2015) [126–134] reports as serotypes of importance in human salmonellosis (Agona, Kentucky, Newport, Hadar, Stanley, Heidelberg, and Saint Paul). Therefore, in order to monitor these serotypes, surveillance of meat and meat products (source of propagation) is required.

4.3. Antibiotic Concentration Analysis According to Each Method Used

The disc diffusion method used in 68.8% of the evaluated studies represents a standard test in various diagnostic laboratories. It is easy to set up, and has a low cost [135,136]. However, to determine MIC in resistance monitoring programs, quantitative tests are preferred due to their accuracy [135,136]. Nonetheless, in the selected reports, MIC analysis was described only for 22.9% of them.

4.4. Salmonella Serotype Resistance Evaluated Using MIC

Among the most used analysis strategies described in the WHO’s “Integrated surveillance of antimicrobial resistance in foodborne bacteria” [137] guide is the percentage calculation of resistant, intermediate, and susceptible isolates. These, in turn, can be stratified as a function of isolation date, geographical location, origin or the frequency of isolations in population studies, allowing for the detection of pathogen’s behaviour in different environments.

In this work, when comparing the MIC methodology, 45.5% of the studies (5/11) reported results as a percentage of prevalence. Of these, in the Clemente et al. (2013) study, 76/127 (59.8%) of the isolates presented serotype I4 [5],12:i:-, which were resistant to AMP STR SUL TET in compliance with the ASSuT phenotype. Within this serotype, 21.3% presented co-resistance to other antibiotics, such as GEN and CHL, demonstrating the presence of multiresistant isolates. Furthermore, three isolates obtained from pork meat products had the blaCTX-M gene, indicating that β-lactamase spread through the food production chain.

In the study by Nhung et al., (2018) isolates from chicken and beef meat were identified; 11 out of 12 isolates with the Kentucky ST 198 serotype were multiresistant. They found resistance to diverse classes of antibiotics such as Cephalosporins, Monobactams, Penicillins, Quinolones, Tetracyclines, and Phenolic compounds. S. Kentucky ST 198 is resistant to cephalosporins, carabapenems, and heavy metals mediated by plasmids. In contrast, resistance to quinolones is due to mutations in topoisomerase encoding genes (gyrA, gyrB, parC, parE). For both cases, resistance resulted from indiscriminate antibiotic prophylactic use in chickens, generating selective pressure [138].

The other three studies are shown in Table S1, where the serotypes Agona, Heidelberg, Indiana, Infantis, Kentucky, Mbandaka, and Thompson were described only once. Serotypes Enteritidis and Typhimurium were reported in two and three studies, respectively. Isolates belonging to S. Enteritidis showed the most resistance to NAL, followed by TET, AMP, and STR. In S. Typhimurium isolates, the most resistant profile was for TET, followed by AMP, NAL, and STR. Salmonella serotypes resistant to Tetracycline have been frequently described in the scientific literature due to the prophylactic use in livestock production, where the most common genes identified are tetA and tetB [139–141]. Nonetheless, in certain countries, Tetracycline use in livestock production is prohibited.

On the other hand, for the 54.5% (6/11) of the studies using MIC (Table 3 and Table S3), the serotype with the highest number of resistance (six classes and ten antibiotics) was the Bredeney serotype reported by Cook et al., (2009). The same study described that this serotype, as previously reported by CIPARS 2003, is frequently observed in clinical isolates from turkey meat. Moreover, the variety of resistances detected by Cook et al. it is noteworthy (2009).
It is also necessary to point out, in the studies performed by Cook et al., (2009) and Gad et al., (2018), a multi-resistance profile was observed which was similar to the Enteritidis, Anatum_var-15+, Montevideo, Saintpaul, and Seftenberg serotypes for the Penicillins, β-lactams, Cephems and Aminoglycosides antibiotics classes (Table 3 and Table S3), where resistance to β-lactams and Aminoglycosides were similar to the ones reported in cattle by Gad et al., (2018), suggesting that containment measures did not work.

*S. Typhimurium* and Enteritidis isolates described in the study by Ahmed et al., (2014) demonstrated a more complex resistance pattern (Table 3 and Table S3), with resistance to 15 antibiotics from 10 different classes in chicken and beef products.

The study also identified antimicrobial resistance molecular mechanisms, among which the integron Class 1 genes (*aadA2* and *bla*<sub>PSE-1</sub> genes), genes coding for β-lactamases (*bla*<sub>TEM-1</sub>, *bla*<sub>CMY-2</sub>, *bla*<sub>CTX-M-3</sub>), genes with resistance to Quinolones (*qnrB*, *aac(6′)-Ib-cr*), and a gene with resistance to Florfenicol (*floR*) were observed. These findings demonstrate how challenging a treatment would be for a patient infected with such an isolate.

4.5. *Salmonella* Serotype Resistance Evaluated Using Disc Diffusion

Table 4 and Table S4 shows that resistance to AMP and CHL was present in all studies, possibly due to the frequent antibiotic use as a prophylactic. These are low-cost, accessible and commonly used antibiotics in some countries for human and poultry production without “medical prescriptions”. Additionally, in the poultry industry, these medications are used as growth promoters and for therapeutic purposes, which trigger antimicrobial resistance in enteric bacterial microbiota. Subsequently, it can be transferred (horizontally and or vertically) to *Salmonella* spp. isolates, allowing multiresistant strains to survive and spread out and ultimately resulting in a public health problem [56,83].

Resistance to Quinolones (NAL) occurred in 10/11 studies (90.9%) in the Typhimurium (6 articles), Enteritidis (5), Kentucky (3), Panama (2), Hadar (2), Anatum (2), Thompson (2), Derby (2), Rissen (2), Muenster (1), Agona (1), Albany (1), Indiana (1), Stanley (1), Schwarzengrund (1), London (1), Mbandaka (1), Corvallis (1) serotypes. Resistance to NAL in Enteritidis and Typhimurium serotypes is considered a public health problem due to human antibiotic use [59]. Furthermore, the use of NAL in human enteric infections has been reconsidered in countries such as Iran [61].

Some countries such as South Korea and Iran use Cephems, Quinolones, and Aminoglycosides (growth promoters or treating bacterial infections) in the poultry industry [69,81,142]. Moreover, the perception regarding Quinolones resistance has changed. For example, in the study by Bada-Alambedji et al., (2006), Quinolones resistance was considered an alarm signal and the last therapeutic resource against *Salmonella* multiresistant isolates. In contrast, in the study by Yang et al., (2019) it was described as one of the most frequently observed antimicrobial resistances.

Resistance to TET was observed in 10/11 studies (90.9%). This antibiotic has been frequently used as a prophylactic growth promoter and food supplement in poultry productions in Iran and porcine productions in Brazil [59,61,92,97]. For humans, the Tetracycline antibiotic class represent a frequent selection in the clinic, hence the importance of surveillance of resistant isolates in livestock production and finished product [143].

Furthermore, as illustrated in Table 5, 248 isolates that were multi-resistant were grouped in 27 different patterns. Noteworthy were AMP and TET, which were present in most patterns. In contrast, NAL, STR, and SXT were uncommon.

NAL resistance is associated with poultry production, due to Quinolone use as a prophylactic [70]. Nevertheless, NAL has also been observed in beef and pork meat [58,72,74,87,95]. STR is not a therapeutic agent against *Salmonella* infections. However, resistance to this antibiotic is an epidemiological marker of the ACSSuT pattern, associated with *S. enterica* serovar Typhimurium phage type DT104 [144].

The AMP SXT TET pattern suggests that these isolates have three different resistance mechanisms (inhibition of cell wall synthesis, inhibition of metabolic factors, and inhibition
of protein synthesis, respectively). Therefore, treatment could be unsuccessful resulting in a public health problem, especially when the isolates come from food products [77].

In addition, the emergent CHL resistance in Brazil [59] and Europe (Council Regulation (EEC) No. 2377/90, Annex IV) [145] resulted in its ban from use in livestock. Hence, the council established zero tolerance to CHL and nitrofurans in food from animal origin, because residues are toxic (causing carcinogenicity and mutagenicity). It has also been reported that antibiotic use alters the resistome of exposed microbial communities and that this effect can persist for decades even after use has ceased [71].

Herein, AMP CHL SXT TET was one of the most common antibiotic patterns and was part of other more complex patterns present in more than one study. Penicillin, sulphonamides, and tetracyclines are the first antimicrobial choice against bacterial infection in poultry diseases. However, their use as a prophylactic can pressure the persistence of resistant phenotypes [95]. Nevertheless, in various studies [74,85,87,89], isolates were also obtained from pork and beef meat.

Finally, in the studies conducted by Gharieb et al. (2015) and Sodagari et al. (2015), the resistance pattern to antibiotics could be different if the authors employed the standard described for the optimal period for CRO, CTX, IMI, and CIP antibiotics.

4.6. Salmonella Serotype Resistance Determined by MIC and Disc Diffusion

Thirteen multi-resistance patterns were determined by MIC and disc diffusion techniques (Table 6), as reported by Molina et al., (2010), Donado-Godoy et al., (2015) and Choi et al., (2015). In the study by Molina et al., (2010), the disc diffusion assay was used to evidence β-lactamase, employing the synergism of double-disc (AMC CAZ CRO CTX ATM). Hence, the thirteen-antimicrobial resistance patterns (Table 6) came from two different techniques.

The most frequently observed antibiotics (Table 6) were AMP, CTX, and TET, followed by CFZ and NAL. The presence of CTX in ten resistance patterns are noteworthy because this is a third-generation cephalosporin (of extended-spectrum and recent synthesis). Additionally, in the article by Donado-Godoy et al., (2015), two isolates of the Heidelberg serotype presented resistance to CTX and CRO (Table 6). Heidelberg serovar is emerging as pathogenic in humans, either due to FBD or zoonosis, and is more invasive than other serovars causing gastroenteritis. Additionally, it generates complications such as septicemia, myocarditis, extra-intestinal infections, and death. A significant temporal correlation has also been demonstrated between the prevalence of Ceftiofur-resistant S. Heidelberg in chicken and human meat in Quebec (Canada) [146,147].

Resistant Salmonella to third and fourth-generation Cephalosporins became a health problem since Cephalosporins are the choice-treatment against invasive salmonellosis in immunosuppressed patients when salmonellosis is due to Fluoroquinolone resistant Salmonella. Likewise, CRO use has intensified in the treatment against infections in children due to CRO’s pharmacokinetic properties [75,79,82].

As with other antibiotics, the increase in Salmonella isolates resistant to Cephalosporins of a broad-spectrum could be conditioned to the use of veterinary treatments. Such is the case for feeding cattle, where Ceftiofur is used in respiratory diseases. It is also used in production practices implemented in some countries such as Japan, where Ceftiofur was used as a disinfectant in chicken embryos and hatched chickens until March 2012 [62,148,149]. Even though this is the case, Ceftiofur use has decreased or has been eliminated in animal production. The problem, however, has worsened since some serovars, such as the Manhattan, maintain the IncX1 plasmid carrying the blaTEM-52 gene [148].

Finally, food production of animal origin is currently changing due to pressure for safer food and new guidelines on the marketing of food of animal origin, among other reasons. Consequently, in some countries, there are already restrictions on the use of antibiotics in animal production. In some cases, producer associations have voluntarily eliminated antibiotics in animal production. In Canada, the chicken industry has voluntarily removed the preventive use of some antimicrobials including Ceftiofur. In the United States, some
producers have opted not to use antibiotics in production, initiatives referred to as either “no antibiotics ever” (NAE) or “raised without antibiotics” (RWA) [142,150,151].

5. Conclusions

The isolates on the articles herein selected came from poultry, cattle, and pigs, where poultry was the predominant source (60% articles). Enteritidis and Typhimurium were the most reported serovars, as evidenced by MIC antimicrobial resistance.

For S. Enteritidis, the highest percentage of resistance was against TET and the lowest was to CIP, while for Typhimurium the highest percentage of resistance was against TET and the lowest was to CRO. The most frequent MIC multi-resistance pattern was against AMP AMC CEP GEN STR TET (five antimicrobial classes and seven antibiotics), observed in Montevideo and Seftenberg. For disc diffusion, the most frequent multi-resistance pattern was AMP STR TET, detected in five articles, specifically for the Bredeney serovar (20%). In the only study that used both MIC and disc diffusion, authors only described percentage of resistance. No similar pattern was observed in the other studies.

Researchers should have more homogeneity in presenting results, sampling procedures, sample type, identification methods, and selection of the appropriate standard [30], as the aforementioned affect the frequency of detection for Salmonella spp., [58].

Lastly, it is necessary to punctuate the importance of Resolution WHA 73.5 compliance for all countries which are members of the WHO [152]. Furthermore, producers of the different guilds must reduce antibiotic prophylactic use in their production.

Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.3390/foods10081731/s1, Table S1. Serovars that were reported in 1 to 3 studies. Table S2. The concentration of antimicrobial agent used in the antimicrobial susceptibility test by MIC. Table S3. Multi-resistance patterns reported once using MIC technique. Table S4. Calculated antimicrobial susceptibility frequency rates of Salmonella serovars using the disc diffusion technique. Table S5. Reported resistance percentages using disc diffusion method. Table S6. Multiresistance patterns described only one for each serovar using the disk diffusion technique.

Author Contributions: Conceptualization, R.A.P.-P.; S.M.R.-G., R.A.P.-P. and A.K.C.-C. analyzed and interpreted the data; S.M.R.-G. wrote the paper; R.A.P.-P. wrote—the reviewer’s answers and edited the manuscript; funding acquisition, S.M.R.-G. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by the “Departamento Administrativo de Ciencia, Tecnología e Innovación” (COLCIENCIAS) Boyacá, Colombia through the project (“Definición de un plan integral de intervención y mitigación con visión de cadena productiva en empresas de derivados cárnicos localizadas en Boyacá”) contract No. FP 44842-186-2017 with “Pontificia Universidad Javeriana”, (PUJ), Bogotá, D.C. Colombia. The APC was funded by “Pontificia Universidad Javeriana, Bogotá D.C., Colombia”.

Data Availability Statement: Data are contained within the article.

Conflicts of Interest: The authors declare that they have no competing interests. Financing entity had no role in the study design, data collection or analysis, decision to publish or preparation of the manuscript.

Abbreviations

Abbreviations for antimicrobial agent reported in the different selected articles and standardized abbreviation.
| Antimicrobial Agent | Abbreviations in the Reports | Abbreviations in This Work |
|---------------------|------------------------------|-----------------------------|
| **Penicillins**     |                              |                             |
| Ampicillin          | AM, AMP, A, Amp, Ap          | AMP                         |
| **β-Lactam/β-Lactamase inhibitor combinations** | | |
| Amoxicillin/clavulanate | AUG, AMC, Amc, AC       | AMC                         |
| Ampicillin-sulbactam | SAM, AS                      | SAM                         |
| Piperacillin-tazobactam | PPC-TAZ, TZP            | TZP                         |
| **Cepheims**        |                              |                             |
| Cefazolin           | CFZ, KZ, CZ, CF, CZD         | CFZ                         |
| Cephalothin         | CF, CEP, CEF, KF            | CEP                         |
| Ceplime            | CFM, FEP                    | FEP                         |
| Cefotaxime          | CTX, TAX, CT                | CTX                         |
| Ceftriazone         | AOX, CRO, Co, CTR           | CRO                         |
| Cefoxitin           | FOX                         | FOX                         |
| Cefuroxime          | FUR, CXM                    | CXM                         |
| Ceftrazidime        | CAZ, CTZ, CF                | CAZ                         |
| Cefoperazone        | CFP                         | CFP                         |
| Cefaclor           | CEC, CFC                    | CFC                         |
| Cefpodoxime         | CPD                         | CPD                         |
| **Monobactams**    |                              |                             |
| Aztreonam         | ATM, AZT, AM                | ATM                         |
| Ertapenem          | ETP                         | ETP                         |
| Imipenem          | IPM, IMP, IMI               | IMI                         |
| Meropenem          | MEM                         | MEM                         |
| **Aminoglycosides**|                              |                             |
| Gentamicin         | GM, G, CN, GE, Gm, GN       | GEN                         |
| Tobramycin         | TOB, To                     | TOB                         |
| Amikacin           | AMI, AM, AMK, AN, Ak        | AMK                         |
| Kanamycin          | KAN, K                      | KAN                         |
| Streptomycin       | S, STR, SM, EST             | STR                         |
| **Fluoroquinolones** |                            |                             |
| Ciprofloxacin      | CIP, Cp, CI, CPE, CPX       | CIP                         |
| Levofloxacin       | Lvx                         | Lvx                         |
| Ofloxacin          | OFX                         | OFX                         |
| Norfloxacin        | NOR                         | NOR                         |
| **Quinolones**     |                              |                             |
| Nalidixic acid     | NA, NAL, Nx, N              | NAL                         |
| **Folate pathway inhibitors** | | |
| Trimethoprim- sulfamethoxazole | SXT, COT, ST, TMP—SLF, TS | SXT                         |
| Sulfonamides       | SSS, SMX, sul, SUL, SMX    | SUL                         |
| Trimethoprim       | TMP, TRIM, TP, W            | TMP                         |
| **Phenicols**      |                              |                             |
| Chloramphenicol    | C, CHL, CM, CLE, CLO, CRO  | CHL                         |
| Nitrofurans        |                              |                             |
| Nitrofurantoin     | FT, NIT                     | NIT                         |
| **Tetracyclines**  |                              |                             |
| Tetracycline       | TE, TET, T, TCY             | TET                         |
27. Mattiello, S.P.; Drescher, G.; Barth, V.C., Jr; Ferreira, C.A.S.; Oliveira, S.D. Characterization of antimicrobial resistance in Salmonella enterica strains isolated from Brazilian poultry production. *Antonie Leeuwenhoek* **2015**, *108*, 1227–1238. [CrossRef]

28. European Food Safety Authority; European Centre for Disease Prevention and Control. The European Union summary report on antimicrobial resistance in zoonotic and indicator bacteria from humans, animals and food in 2016. *EFSA J.* **2018**, *16*, e05182.

29. Kiska, D.L. In vitro testing of antimicrobial agents. *Semin. Pediatr. Infect. Dis.* **1998**, *9*, 281–291. [CrossRef]

30. Rincón-Gamboa, S.M.; Poutou-Piñales, R.A.; Carrascal-Camacho, A.K. Analysis of the assessment of antimicrobial susceptibility. Non-typhoidal *Salmonella* in meat and meat products as model (systematic review). *BMC Microbiol.* **2021**, in press.

31. Page, M.J.; McKenzie, J.E.; Bossuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D.; Shamseer, L.; Tetzlaff, J.M.; Akl, E.A.; Brennan, S.E.; et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. *BMJ* **2021**, *372*, n71. [CrossRef] [PubMed]

32. Haddaway, N.R.; McGuinness, L.A. PRISMA2020: R Package and ShinyApp for Producing PRISMA 2020 Compliant Flow Diagrams, version 0.0.1; Zenodo: Geneva, Switzerland, 2020. Available online: https://zenodo.org/record/4287835#.YOLLCUxRVhE (accessed on 20 January 2021).

33. National Committee for Clinical Laboratory Standards. *Performance Standards for Antimicrobial Susceptibility Testing* (NCCLS M100-S9); National Committee for Clinical Laboratory Standards: Albany, NY, USA, 1999; p. 320.

34. National Committee for Clinical Laboratory Standards. *Performance Standards for Antimicrobial Susceptibility Testing* (NCCLS M100-S11); National Committee for Clinical Laboratory Standards: Albany, NY, USA, 2000.

35. National Committee for Clinical Laboratory Standards. *Performance Standards for Antimicrobial Susceptibility Testing* (NCCLS M100-S13); National Committee for Clinical Laboratory Standards: Albany, NY, USA, 2003.

36. Clinical and Laboratory Standards Institute. *Performance Standards for Antimicrobial Susceptibility Testing* (M100-S15); National Committee for Clinical Laboratory Standards: Albany, NY, USA, 2005; p. 172.

37. Clinical and Laboratory Standards Institute. *Performance Standards for Antimicrobial Susceptibility Testing* (CLSI M100-S16); National Committee for Clinical Laboratory Standards: Albany, NY, USA, 2006; p. 188.

38. Clinical and Laboratory Standards Institute. *Performance Standards for Antimicrobial Susceptibility Testing* (CLSI M100-S17); National Committee for Clinical Laboratory Standards: Albany, NY, USA, 2007; p. 182.

39. Clinical and Laboratory Standards Institute. *Performance Standards for Antimicrobial Susceptibility Testing* (CLSI M100-S18); National Committee for Clinical Laboratory Standards: Albany, NY, USA, 2008; p. 188.

40. Clinical and Laboratory Standards Institute. *Performance Standards for Antimicrobial Susceptibility Testing* (CLSI M100-S19); National Committee for Clinical Laboratory Standards: Albany, NY, USA, 2009.

41. Clinical and Laboratory Standards Institute. *Performance Standards for Antimicrobial Susceptibility Testing* (CLSI M100-S20); National Committee for Clinical Laboratory Standards: Albany, NY, USA, 2010; p. 160.

42. Clinical and Laboratory Standards Institute. *Performance Standards for Antimicrobial Susceptibility Testing* (CLSI M100-S21); National Committee for Clinical Laboratory Standards: Albany, NY, USA, 2011; p. 172.

43. Clinical and Laboratory Standards Institute. *Performance Standards for Antimicrobial Susceptibility Testing* (CLSI M100-S22); National Committee for Clinical Laboratory Standards: Albany, NY, USA, 2012; p. 188.

44. Clinical and Laboratory Standards Institute. *Performance Standards for Antimicrobial Susceptibility Testing* (CLSI M100-S23); National Committee for Clinical Laboratory Standards: Albany, NY, USA, 2013; p. 206.

45. Clinical and Laboratory Standards Institute. *Performance Standards for Antimicrobial Susceptibility Testing* (CLSI M100-S24); National Committee for Clinical Laboratory Standards: Albany, NY, USA, 2014; p. 230.

46. Clinical and Laboratory Standards Institute. *Performance Standards for Antimicrobial Susceptibility Testing* (CLSI M100-S25); National Committee for Clinical Laboratory Standards: Albany, NY, USA, 2015; p. 240.

47. Clinical and Laboratory Standards Institute. *Performance Standards for Antimicrobial Susceptibility Testing* (CLSI M100-S26); National Committee for Clinical Laboratory Standards: Albany, NY, USA, 2018; p. 296.

48. Comité de l’Antibiogramme de la Société Française de Microbiologie. Communiqué 1997. *Pathologie Biologie (Paris)*; Société Française de Microbiologie: Paris, France, 1997.

49. European Committee on Antimicrobial Susceptibility Testing. *Breakpoint Tables for Interpretation of MICs and Zone Diameters, version 2.0*; European Committee on Antimicrobial Susceptibility Testing: Växjö, Sweden, 2012.

50. Department of Health and Human Services; Centers for Disease Control and Prevention; Food and Drug Administration; United States Department of Agriculture. *National Antimicrobial Resistance Monitoring System (NARMS)*. 2011 Executive Report; Department of Health and Human Services: Washington, DC, USA, 2011; p. 123.

51. Public Health Agency of Canada. *Canadian Integrated Program. for Antimicrobial Resistance Surveillance (CIPARS)* 2003 Report; Public Health Agency of Canada: Guelph, ON, Canada, 2005.

52. Clinical and Laboratory Standards Institute. *Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated from Animals* (NCCLS M31-S1); Clinical and Laboratory Standards Institute: Annapolis Junction, MD, USA, 2004; p. 40.

53. Clinical and Laboratory Standards Institute. *Performance Standards for Antimicrobial Disk and Dilution susceptibility Tests for Bacteria Isolated from Animals* (NCCLS M31-A2); Clinical and Laboratory Standards Institute: Annapolis Junction, MD, USA, 2002; p. 80.

54. Clinical and Laboratory Standards Institute. *Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated From Animals* (CLSI M31-A3); Clinical and Laboratory Standards Institute: Annapolis Junction, MD, USA, 2008; p. 116.
55. Fakhr, M.K.; Sherwood, J.S.; Thorsness, J.; Logue, C.M. Molecular characterization and antibiotic resistance profiling of *Salmonella* isolated from retail turkey meat products. *Foodborne Pathog. Dis.* 2006, 3, 366–374. [CrossRef] [PubMed]

56. Bada-Alameddi, R.; Ofana, A.; Seydi, M.; Akakpo, A.J. Antimicrobial resistance of *Salmonella* isolated from poultry carcasses in Dakar (Senegal). *Braz. J. Microbiol.* 2006, 37, 510–515. [CrossRef]

57. Valdezate, S.; Arroyo, M.; Gonzalez-Sanz, R.; Ramiro, R.; Herrera-León, C.; Usera, M.A.; De La Fuente, M.; Echeita, A. Antimicrobial resistance and phage and molecular typing of *Salmonella* strains isolated from food for human consumption in Spain. *J. Food Prot.* 2007, 70, 2741–2748. [CrossRef] [PubMed]

58. Van, T.T.H.; Moutafis, G.; Istivan, T.; Tran, L.T.; Coloe, P.J. Detection of *Salmonella* spp. in retail raw food samples from Vietnam and Characterization of their antibiotic resistance. *Appl. Environ. Microbiol.* 2007, 73, 6885–6890. [CrossRef] [PubMed]

59. Murmann, L.; dos Santos, M.C.; Cardoso, M. Prevalence, genetic characterization and antimicrobial resistance of *Salmonella* isolated from fresh pork sausages in Porto Alegre, Brazil. *Food Cont.* 2009, 20, 191–195. [CrossRef]

60. Cook, A.; Reid-Smith, R.; Irwin, R.; Mcewen, S.A.; Valdivieso-Garcia, A.; Ribble, C. Antimicrobial resistance in Campylobacter, *Salmonella*, and *Escherichia coli* isolated from retail Turkey meat from Southern Ontario, Canada. *J. Food Prot.* 2009, 72, 473–481. [CrossRef]

61. Soltan Dallal, M.M.; Doyle, M.P.; Rezadehbashi, M.; Dabiri, H.; Sanaei, M.; Modarresi, S.; Bakhtiari, R.; Sharifiy, K.; Taremi, Z.; Mazaraki, K.; Vafeas, G.; Giantzi, V.; Papadopoulos, T.; Ekateriniadou, L. Prevalence, seasonal occurrence and antimicrobial resistance patterns of *Salmonella enterica* serotypes isolated from poultry in Spain: Comparison between 1993 and 2006. *Int. J. Food Microbiol.* 2010, 141, 1405–1415. [CrossRef]

62. Molina, N.; Millán, B.; Araque, M. Indicadores de calidad sanitaria y fenotipificación de *Salmonella enterica* aislado de pollo crudo comercializado en el área urbana de Mérida, Venezuela. *Rev. Infect.* 2010, 14, 174–185. [CrossRef]

63. Sirichote, P.; Bangtrakulnonth, A.; Tianmanee, K.; Unahalekhaka, A.; Oulai, A.; Chittaphithakchai, P.; Chiewpraphai, P.; Kheowrod, W.; Hendriksen, R.S. Serotypes and antimicrobial resistance of *Salmonella enterica* spp in central Thailand, 2001–2006. *SE Asian J. Trop. Med.* 2010, 41, 328–334. [CrossRef]

64. Mikantha, N.M.; Sandt, C.H.; Localio, A.R.; Tewari, D.; Rankin, S.C.; Whichard, J.M.; Altekruse, S.F.; Lautenbach, E.; Folster, J.P.; Russo, A.; et al. Multidrug-resistant *Salmonella* isolates from retail chicken meat compared with human clinical isolates. *Foodborne Pathog. Dis.* 2010, 1405–1415. [CrossRef]

65. Hyeon, J.-Y.; Chon, J.-W.; Hwang, I.-G.; Kwak, H.-S.; Kim, M.-S.; Kim, S.-K.; Choi, I.-S.; Song, C.-S.; Park, C.; Sea, K.-H. Prevalence, antibiotic resistance, and molecular characterization of antimicrobial resistance in *Salmonella enterica* serovars in retail meat products. *J. Food Prot.* 2011, 74, 161–166. [CrossRef]

66. Nunes Medeiros, M.A.; Nunes de Oliveira, D.C.; Rodrigues, D.d.P.; Coradi de Freitas, D.R. Prevalence and antimicrobial resistance of *Salmonella* in chicken carcasses at retail in 15 Brazilian cities. *Rev. Panam. Salud Publica* 2011, 30, 555–560. [CrossRef]

67. Aslam, M.; Checkley, S.; Avery, B.; Chalmers, G.; Bohaychuk, V.; Gensler, G.; Reid-Smith, R.; Boerlin, P. Phenotypic and genetic characterization of antimicrobial resistance in *Salmonella enterica* serovars isolated from retail meats in Alberta, Canada. *Food Microbiol.* 2012, 32, 110–117. [CrossRef]

68. Thai, T.H.; Lan, N.T.; Hirai, T.; Yamaguchi, R. Antimicrobial resistance in *Salmonella enterica* serovars isolated from meat shops at the markets in North Vietnam. *Foodborne Pathog. Dis.* 2012, 9, 986–991. [CrossRef]

69. Kim, M.-S.; Lim, T.-H.; Jang, J.-H.; Lee, D.-H.; Kim, B.-Y.; Kwon, J.-H.; Choi, S.; Song, S.-G.; Park, C.; Sea, K.-H.; et al. Prevalence and antimicrobial resistance of *Salmonella* species isolated from chicken meats produced by different integrated broiler operations in Korea. *Poult. Sci.* 2012, 91, 2370–2375. [CrossRef]

70. Zdragas, A.; Mazarakis, V.; Vafeas, G.; Gianzi, V.; Papadopoulos, T.; Ekateriniadou, L. Prevalence, seasonal occurrence and antimicrobial resistance of *Salmonella enterica* in poultry retail products in Greece. *Leit. Appl. Microbiol.* 2012, 35, 308–313. [CrossRef] [PubMed]

71. Álvarez-Fernández, E.; Alonso-Calleja, C.; García-Fernández, C.; Capita, R. Prevalence and antimicrobial resistance of *Salmonella* serotypes isolated from poultry in Spain: Comparison between 1993 and 2006. *Int. J. Food Microbiol.* 2012, 153, 281–287. [CrossRef]

72. Cabrera-Diaz, E.; Barbosa-Cardenas, C.M.; Perez-Montaño, J.A.; Gonzalez-Aguilar, D.; Pacheco-Gallardo, C.; Barba, J. Occurrence, serotype diversity, and antimicrobial resistance of *Salmonella enterica* in ground beef at retail stores in Jalisco state, Mexico. *J. Food Prot.* 2013, 76, 2004–2010. [CrossRef] [PubMed]

73. Clemente, L.; Mano, J.; Ferreira, E.; Jones-Dias, D.; Correia, I.; Themudo, P.; Albuquerque, T.; Caniça, M. Occurrence of extended-spectrum β-lactamases among isolates of *Salmonella enterica* subsp. *enterica* from food-producing animals and food products, in Portugal. *Int. J. Food Microbiol.* 2013, 167, 213–227. [CrossRef]

74. Li, Y.-C.; Pan, Z.-M.; Kang, X.-L.; Geng, S.-Z.; Liu, Z.-Y.; Cai, Y.-Q.; Jiao, X.-A. Prevalence, characteristics, and antimicrobial resistance patterns of *Salmonella enterica* in retail pork in Jiangsu Province, Eastern China. *J. Food Prot.* 2014, 77, 236–245. [CrossRef] [PubMed]

75. Bacci, C.; Lanzoni, E.; Vismarra, A.; Alpigiani, I.; Nuvoloni, R.; Bonardi, S.; Brindani, F. Antibiotic resistance and resistance genes in *Salmonella enterica* isolated from pork meat and pig carcasses in Northern Italy. *Large Anim. Rev.* 2014, 20, 201–207.
87. Niyomdecha, N.; Mungkornkaew, N.; Samosornsuk, W. Serotypes and antimicrobial resistance of Salmonella enterica in raw chicken and beef meat in northern Egypt and dissemination of their antibiotic resistance markers. Food Prot. Lett. 2015, 7, 1888–1893. [CrossRef] [PubMed]

88. Thung, T.Y.; Mahyudin, N.A.; Basri, D.F.; Waq Mohamed Radzi, C.W.J.; Nakaguchi, Y.; Nishibuchi, M.; Radu, S. Prevalence and antibiotic resistance of Salmonella enteritidis and Salmonella typhimurium in raw chicken meat at retail markets in Malaysia. Poult. Sci. 2016, 95, 56–64. [CrossRef] [PubMed]

89. Nghi, M.N.; Nguyen, V.T.; Nguyen, T.T.H.; Nguyen, T.D.; Vo, T.T.B. Antimicrobial resistance gene expression associated with multidrug resistant Salmonella spp. isolated from retail meat in Hanoi, Vietnam. Int. Microbiol. 2017, 20, 85–93. [PubMed]

90. Moawad, A.A.; Hotzel, H.; Awad, O.; Tomaso, H.; Neubauer, H.; Hafez, H.M.; El-Adawy, H. Occurrence of Salmonella enterica and Escherichia coli in raw chicken and beef meat in northern Egypt and dissemination of their antibiotic resistance markers. Gut Pathog. 2017, 9, 57. [CrossRef] [PubMed]

91. Gad, A.H.; Ab-Shama, U.H.; Harclerode, K.K.; Fakhr, M.K. Prevalence, serotyping, molecular typing, and antimicrobial resistance of Salmonella isolated from conventional and organic retail ground poultry. Front. Microbiol. 2018, 9, 2653. [CrossRef]

92. Zhang, L.; Fu, Y.; Xiong, Z.; Ma, Y.; Wei, Y.; Qu, X.; Zhang, H.; Zhang, J.; Liao, M. Highly prevalent multidrug-resistant Salmonella from chicken and pork meat at retail markets in Guangdong, China. Front. Microbiol. 2018, 9, 2104. [CrossRef]

93. Nhung, N.T.; Van, N.T.B.; Cuong, N.V.; Duong, T.Q.; Nhat, T.T.; Hang, T.T.T.; Nhi, N.T.H.; Kiet, B.T.; Hien, V.B.; Ngoc, P.T.; et al. Antimicrobial residues and resistance against critically important antimicrobials in non-typhoidal Salmonella from meat sold at wet markets and supermarkets in Vietnam. Int. J. Food Microbiol. 2018, 266, 301–309. [CrossRef]

94. Thung, T.Y.; Radu, S.; Mahyudin, N.A.; Rukayadi, Y.; Zakaria, Z.; Mazlan, N.; Tan, B.H.; Lee, E.; Yeoh, S.L.; Chin, Y.Z.; et al. Prevalence, virulence genes and antimicrobial resistance profiles of Salmonella serovars from retail beef in Selangor, Malaysia. Front. Microbiol. 2018, 8, 2697. [CrossRef] [PubMed]

95. Zee, Y.H.; Tang, V.C.Y.; Aung, K.T.; Alikiiteaga Gutierrez, R.; Ng, L.C.; Yuk, H.-G. Prevalence, sequence types, antibiotic resistance and, gyrA mutations of Salmonella isolated from retail fresh chicken meat in Singapore. Food Cont. 2018, 90, 233–240. [CrossRef]

96. Zhu, A.; Zhi, W.; Qiu, Y.; Wei, L.; Tian, J.; Pan, Z.; Kang, X.; Gu, W.; Duan, L. Surveillance study of the prevalence and antimicrobial resistance of Salmonella from pork in open markets in Xuzhou, China. Food Cont. 2019, 98, 474–480. [CrossRef]

97. Yang, X.; Wu, Q.; Zhang, J.; Huang, J.; Chen, L.; Wu, S.; Zeng, H.; Wang, J.; Chen, M.; Wu, H.; et al. Prevalence, bacterial load, and antimicrobial resistance of Salmonella serovars isolated from retail meat and meat products in China. Front. Microbiol. 2019, 10, 2121. [CrossRef]

98. Cheng, R.A.; Eade, C.R.; Wiedmann, M. Embracing diversity: Differences in virulence mechanisms, disease severity, and host adaptations contribute to the success of nontyphoidal Salmonella as a foodborne pathogen. Front. Microbiol. 2019, 10, 1368. [CrossRef]

99. Ao, T.T.; Feasey, N.A.; Gordon, M.A.; Keddy, K.H.; Angulo, F.J.; Crump, J.A. Global burden of invasive nontyphoidal Salmonella disease, 2010. Emerg. Infect. Dis. 2015, 21, 941. [CrossRef] [PubMed]

100. Wallis, T.S.; Barrow, P.A. Salmonella epidemiology and pathogenesis in food-producing animals. EcoSas Plus 2005, 1. [CrossRef] [PubMed]
102. Quan, G.; Xia, P.; Zhao, J.; Zhu, C.; Meng, X.; Yang, Y.; Wang, Y.; Tian, Y.; Ding, X.; Zhu, G. Fimbriae and related receptors for *Salmonella enteritidis*. *Microb. Pathog.* 2019, 126, 357–362. [CrossRef]

103. Chiou, C.-S.; Hong, Y.-P.; Liao, Y.-S.; Wang, Y.-W.; Tu, Y.-H.; Chen, B.-H.; Chen, Y.-S. New multidrug-resistant *Salmonella enterica* serovar Anatum clone, Taiwan, 2015–2017. *Emerg. Infect. Dis.* 2019, 25, 144–147. [CrossRef] [PubMed]

104. Valdezate, S.; Vidal, A.; Herrera-León, S.; Pojo, J.; Rubió, P.; Usera, M.A.; Carvajal, A.; Echeita, M.A. *Salmonella derby* clonal spread from pork. *Emerg. Infect. Dis.* 2005, 11, 694–698. [CrossRef]

105. Fernandes Inagaki, J.M.; Jagnow Sereno, M.; Pegoraro, K.; Zanatta Waz, M.; Mendonça Soares, V.; Gonçalves Pereira, J.; Bersot, L.D.S. Effect of organic matter and pH on the resistance of *Salmonella typhimurium* and *Salmonella derby* in scalding water from pig slaughter. *J. Food Saf.* 2018, 38, e12504. [CrossRef]

106. Centers for Disease Control and Prevention; National Center for Infectious Diseases; Division of Bacterial and Mycotic Diseases; Foodborne and Diarrheal Diseases Branch. *Human Isolates Surveillance Report; Enteric Diseases Epidemiology Branch, Division of Foodborne, Bacterial, and Mycotic Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases, Centers for Disease Control and Prevention: Atlanta, GA, USA, 2015.*

107. Centers for Disease Control and Prevention; National Center for Infectious Diseases; Division of Bacterial and Mycotic Diseases; Foodborne and Diarrheal Diseases Branch. *Human Isolates Surveillance Report; Enteric Diseases Epidemiology Branch, Division of Foodborne, Bacterial, and Mycotic Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases, Centers for Disease Control and Prevention: Atlanta, GA, USA, 2014.*

108. Centers for Disease Control and Prevention. Available online: https://www.cdc.gov/tularemia/index.html (accessed on 10 July 2013).

109. Centers for Disease Control and Prevention; National Center for Infectious Diseases; Division of Bacterial and Mycotic Diseases; Foodborne and Diarrheal Diseases Branch. *Human Isolates Final Report; Enteric Diseases Epidemiology Branch, Division of Foodborne, Bacterial, and Mycotic Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases, Centers for Disease Control and Prevention: Atlanta, GA, USA, 2013.*

110. Centers for Disease Control and Prevention; National Center for Infectious Diseases; Division of Bacterial and Mycotic Diseases; Foodborne and Diarrheal Diseases Branch. *Human Isolates Final Report; Enteric Diseases Epidemiology Branch, Division of Foodborne, Bacterial, and Mycotic Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases, Centers for Disease Control and Prevention: Atlanta, GA, USA, 2012.*

111. Centers for Disease Control and Prevention; National Center for Infectious Diseases; Division of Bacterial and Mycotic Diseases; Foodborne and Diarrheal Diseases Branch. *Human Isolates Final Report; Enteric Diseases Epidemiology Branch, Division of Foodborne, Bacterial, and Mycotic Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases, Centers for Disease Control and Prevention: Atlanta, GA, USA, 2011.*

112. Centers for Disease Control and Prevention; National Center for Infectious Diseases; Division of Bacterial and Mycotic Diseases; Foodborne and Diarrheal Diseases Branch. *Human Isolates Final Report; Enteric Diseases Epidemiology Branch, Division of Foodborne, Bacterial, and Mycotic Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases, Centers for Disease Control and Prevention: Atlanta, GA, USA, 2010.*

113. Centers for Disease Control and Prevention; National Center for Infectious Diseases; Division of Bacterial and Mycotic Diseases; Foodborne and Diarrheal Diseases Branch. *Human Isolates Final Report; Enteric Diseases Epidemiology Branch, Division of Foodborne, Bacterial, and Mycotic Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases, Centers for Disease Control and Prevention: Atlanta, GA, USA, 2009.*

114. Centers for Disease Control and Prevention; National Center for Infectious Diseases; Division of Bacterial and Mycotic Diseases; Foodborne and Diarrheal Diseases Branch. *Human Isolates Final Report; Enteric Diseases Epidemiology Branch, Division of Foodborne, Bacterial, and Mycotic Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases, Centers for Disease Control and Prevention: Atlanta, GA, USA, 2008.*

115. Centers for Disease Control and Prevention; National Center for Infectious Diseases; Division of Bacterial and Mycotic Diseases; Foodborne and Diarrheal Diseases Branch. *Human Isolates Final Report; Enteric Diseases Epidemiology Branch, Division of Foodborne, Bacterial, and Mycotic Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases, Centers for Disease Control and Prevention: Atlanta, GA, USA, 2007.*

116. Centers for Disease Control and Prevention; National Center for Infectious Diseases; Division of Bacterial and Mycotic Diseases; Foodborne and Diarrheal Diseases Branch. *Human Isolates Final Report; Enteric Diseases Epidemiology Branch, Division of Foodborne, Bacterial, and Mycotic Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases, Centers for Disease Control and Prevention: Atlanta, GA, USA, 2006.*

117. Centers for Disease Control and Prevention; National Center for Infectious Diseases; Division of Bacterial and Mycotic Diseases; Foodborne and Diarrheal Diseases Branch. *Human Isolates Final Report; Enteric Diseases Epidemiology Branch, Division of Foodborne, Bacterial, and Mycotic Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases, Centers for Disease Control and Prevention: Atlanta, GA, USA, 2005.*

118. Centers for Disease Control and Prevention; National Center for Infectious Diseases; Division of Bacterial and Mycotic Diseases; Foodborne and Diarrheal Diseases Branch. *Human Isolates Final Report; Enteric Diseases Epidemiology Branch, Division of Foodborne, Bacterial, and Mycotic Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases, Centers for Disease Control and Prevention: Atlanta, GA, USA, 2004.*
119. Centers for Disease Control and Prevention; National Center for Infectious Diseases; Division of Bacterial and Mycotic Diseases; Foodborne and Diarrheal Diseases Branch. Human Isolates Final Report. Enteric Diseases Epidemiology Branch, Division of Foodborne, Bacterial, and Mycotic Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases, Centers for Disease Control and Prevention: Atlanta, GA, USA, 2003.

120. Centers for Disease Control and Prevention; National Center for Infectious Diseases; Division of Bacterial and Mycotic Diseases; Foodborne and Diarrheal Diseases Branch. National Antimicrobial Resistance Monitoring System (NARMS): Enteric Bacteria; Enteric Diseases Epidemiology Branch, Division of Foodborne, Bacterial, and Mycotic Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases, Centers for Disease Control and Prevention: Atlanta, GA, USA, 2002.

121. Centers for Disease Control and Prevention; National Center for Infectious Diseases; Division of Bacterial and Mycotic Diseases; Foodborne and Diarrheal Diseases Branch. National Antimicrobial Resistance Monitoring System (NARMS) 2001 Annual Report Summary; Enteric Diseases Epidemiology Branch, Division of Foodborne, Bacterial, and Mycotic Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases, Centers for Disease Control and Prevention: Atlanta, GA, USA, 2001.

122. Centers for Disease Control and Prevention; National Center for Infectious Diseases; Division of Bacterial and Mycotic Diseases; Foodborne and Diarrheal Diseases Branch. National Antimicrobial Resistance Monitoring System (NARMS): Enteric Bacteria; Enteric Diseases Epidemiology Branch, Division of Foodborne, Bacterial, and Mycotic Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases, Centers for Disease Control and Prevention: Atlanta, GA, USA, 2000.

123. Centers for Disease Control and Prevention; National Center for Infectious Diseases; Division of Bacterial and Mycotic Diseases; Foodborne and Diarrheal Diseases Branch. National Antimicrobial Resistance Monitoring System (NARMS) 1999 Annual Report Summary; Enteric Diseases Epidemiology Branch, Division of Foodborne, Bacterial, and Mycotic Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases, Centers for Disease Control and Prevention: Atlanta, GA, USA, 1999.

124. Centers for Disease Control and Prevention; National Center for Infectious Diseases; Division of Bacterial and Mycotic Diseases; Foodborne and Diarrheal Diseases Branch. National Antimicrobial Resistance Monitoring System (NARMS) 1998 Annual Report Summary; Enteric Diseases Epidemiology Branch, Division of Foodborne, Bacterial, and Mycotic Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases, Centers for Disease Control and Prevention: Atlanta, GA, USA, 1998.

125. Centers for Disease Control and Prevention; National Center for Infectious Diseases; Division of Bacterial and Mycotic Diseases; Foodborne and Diarrheal Diseases Branch. National Antimicrobial Resistance Monitoring System (NARMS) 1997 Annual Report Summary; Enteric Diseases Epidemiology Branch, Division of Foodborne, Bacterial, and Mycotic Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases, Centers for Disease Control and Prevention: Atlanta, GA, USA, 1997.

126. European Food Safety Authority (EFSA). Trends and sources of zoonoses, zoonotic agents and food-borne outbreaks in the European Union in 2008. EFSA J. 2010, 8, 1496.

127. European Food Safety Authority (EFSA). The community summary report on trends and sources of zoonoses and zoonotic agents in the European Union in 2007. EFSA J. 2009, 7, 233r.

128. European Food Safety Authority (EFSA). The community summary report on trends and sources of zoonoses, zoonotic agents, antimicrobial resistance and foodborne outbreaks in the European Union in 2005. EFSA J. 2006, 94, 288.

129. European Food Safety Authority (EFSA). Trends and sources of zoonoses, zoonotic agents and antimicrobial resistance in the European Union in 2004. EFSA J. 2006, 310, 280.

130. European Food Safety Authority (EFSA); European Centre for Disease Prevention and Control (ECDC). The European Union summary report on trends and sources of zoonoses, zoonotic agents and food-borne outbreaks in 2012. EFSA J. 2014, 12, 3547.

131. European Food Safety Authority (EFSA); European Centre for Disease Prevention and Control (ECDC). The European Union summary report on trends and sources of zoonoses, zoonotic agents and food-borne outbreaks in 2011. EFSA J. 2013, 11, 3129.

132. European Food Safety Authority (EFSA); European Centre for Disease Prevention and Control (ECDC). The European Union summary report on trends and sources of zoonoses, zoonotic agents and food-borne outbreaks in 2010. EFSA J. 2012, 10, 2597.

133. European Food Safety Authority (EFSA); European Centre for Disease Prevention and Control (ECDC). The European Union summary report on trends and sources of zoonoses, zoonotic agents and food-borne outbreaks in 2009. EFSA J. 2011, 9, 2090.

134. European Food Safety Authority (EFSA); European Centre for Disease Prevention and Control (ECDC). The European Union summary report on trends and sources of zoonoses, zoonotic agents and food-borne outbreaks in 2013. EFSA J. 2015, 13, 3991. [CrossRef]

135. de Jong, A.; Moyaert, H.; Simjee, S. Antimicrobial susceptibility testing of foodborne bacteria related to national and international resistance-monitoring programs. In Antimicrobial Food Packaging; Barros-Velázquez, J., Ed.; Academic Press: Brussels, Belgium, 2016; pp. 117–128.

136. Nassar, M.S.M.; Hazzah, W.A.; Bakr, W.M.K. Evaluation of antibiotic susceptibility test results: How guilty a laboratory could be? Egypt. Public Health Assoc. 2019, 94, 4. [CrossRef]

137. World Health Organization Advisory Group on Integrated Surveillance of Antimicrobial Resistance; Food and Agriculture Organization of the United Nations; World Organisation for Animal Health. Integrated Surveillance of Antimicrobial Resistance in Foodborne Bacteria: Application of a one Health Approach; World Health Organization: Geneva, Switzerland, 2017.

138. Wasyl, D.; Kern-Zdanowicz, I.; Doman’ ska-Blicharz, K.; Zajac, M.; Hoszowski, A. High-level fluoroquinolone resistant Salmonella enterica serovar Kentucky ST198 epidemic clone with IncA/C conjugative plasmid carrying blaCTX-M-25 gene. Vet. Microbiol. 2015, 175, 85–91. [CrossRef]
139. Louden, B.C.; Haarmann, D.; Han, J.; Foley, S.L.; Lynne, A.M. Characterization of antimicrobial resistance in Salmonella enterica serovar typhimurium isolates from food animals in the U.S. Food Res. Int. 2012, 45, 968–972. [CrossRef]

140. Dessie, H.K.; Bae, D.H.; Lee, Y.J. Characterization of integrons and their cassettes in Escherichia coli and Salmonella isolates from poultry in Korea. Poult. Sci. 2013, 92, 3036–3043. [CrossRef] [PubMed]

141. Samanta, I.; Bandypadhyay, S. Characteristics of antimicrobial resistance among microorganisms of concern to animal, fish and human health: Salmonella. In Antimicrobial Resistance in Agriculture: Perspective, Policy and Mitigation; Academic Press: London, UK, 2020; pp. 136–150.

142. Antunes, P.; Mourao, J.; Campos, J.; Peixe, L. Salmonellosis: The role of poultry meat. Clin. Microbiol. Infect. 2016, 22, 110–121. [CrossRef] [PubMed]

143. Grossman, T.H. Tetracycline antibiotics and resistance. Perspect. Med. 2016, 6, a025387. [CrossRef]

144. Doran, G.; NiChulain, M.; DeLappe, N.; O’Hare, C.; Corbett-Feeney, G.; Cormican, M. Interpreting streptomycin susceptibility test results for Salmonella enterica serovar typhimurium. Int. J. Antimicrob. Agents 2006, 27, 538–540. [CrossRef] [PubMed]

145. Council Regulation (EEC). Laying down a community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (No. 2377/90). Off. J. Eur. Comunities 1990, 224, 1–8.

146. Dutil, L.; Irwin, R.; Finley, R.; Ng, L.K.; Avery, B.; Boerlin, P.; Bourgault, A.-M.; Cole, L.; Daignault, D.; Desruisseau, A.; et al. Ceftiofur resistance in Salmonella enterica serovar Heidelberg from chicken meat and humans, Canada. Emerg. Infect. Dis. 2010, 16, 48–55. [CrossRef]

147. Otto, S.J.G.; Carson, C.A.; Finley, R.L.; Thomas, M.K.; Reid-Smith, R.J.; McEwen, S.A. Estimating the number of human cases of ceftiofur-resistant Salmonella enterica serovar Heidelberg in Québec and Ontario, Canada. Clin. Infect. Dis. 2014, 59, 1–90. [CrossRef]

148. Shigemura, H.; Matsui, M.; Sekizuka, T.; Onozuka, D.; Noda, T.; Yamashita, A.; Kuroda, M.; Suzuki, S.; Kimura, H.; Fujimoto, S.; et al. Decrease in the prevalence of extended-spectrum cephalosporin-resistant Salmonella following cessation of ceftiofur use by the Japanese poultry industry. Int. J. Food Microbiol. 2018, 274, 45–51. [CrossRef]

149. Ohta, N.; Norby, B.; Loneragan, G.H.; Vinasco, J.; den Bakker, H.C.; Lawhon, S.D.; Norman, K.N.H.M. Scott Quantitative dynamics of Salmonella and E. coli in feces of feedlot cattle treated with ceftiofur and chlorotetracycline. PLoS ONE 2019, 14, e0225697. [CrossRef]

150. Collineau, L.; Chapman, B.; Bao, X.; Sivapathasundaram, B.; Carson, C.A.; Fazil, A.; Reid-Smith, R.J.; Smith, B.A. A farm-to-fork quantitative risk assessment model for Salmonella Heidelberg resistant to third-generation cephalosporins in broiler chickens in Canada. Int. J. Food Microbiol. 2020, 330, 108559. [CrossRef]

151. Choi, J.; Kim, W.K. Dietary application of tannins as a potential mitigation strategy for current challenges in poultry production: A review. Animals 2020, 10, 2389. [CrossRef] [PubMed]

152. Seventy-third World Health Assembly. (WHA 73.5) Strengthening Efforts on Food Safety; World Health Organization: Geneva, Switzerland, 2020; p. 5.